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OBJECTIVES This study was designed to assess the safety of arteriotomy closure devices (ACDs) versus
mechanical compression by meta-analysis in patients undergoing percutaneous transfemoral
coronary procedures.
BACKGROUND Although ACDs are widely applied for hemostasis after percutaneous endovascular proce-
dures, their safety is controversial.
METHODS Randomized, case-control, and cohort studies comparing access-related complications using
ACDs versus mechanical compression were analyzed. The primary end point was the
cumulative incidence of vascular complications, including pseudoaneurysm, arteriovenous
fistula, retroperitoneal hematoma, femoral artery thrombosis, surgical vascular repair, access
site infection, and blood transfusion.
RESULTS A total of 30 studies involving 37,066 patients were identified. No difference in complication
incidence between Angio-Seal and mechanical compression was revealed in the diagnostic
(Dx) setting (odds ratio [OR] 1.08, 95% confidence interval [CI] 0.11 to 10.0) or
percutaneous coronary interventions (PCI) (OR 0.86, 95% CI 0.65 to 1.12). Meta-analysis of
randomized trials only showed a trend toward less complications using Angio-Seal in a PCI
setting (OR 0.46, 95% CI 0.20 to 1.04; p  0.062). No differences were observed regarding
Perclose in either Dx (OR 1.51, 95% CI 0.24 to 9.47) or PCI (OR 1.21, 95% CI 0.94 to 1.54)
setting. An increased risk in complication rates using VasoSeal in the PCI setting (OR 2.25,
95% CI 1.07 to 4.71) was found. The overall analysis favored mechanical compression over
ACD (OR 1.34, 95% CI 1.01 to 1.79).
CONCLUSIONS In the setting of Dx angiography, the risk of access-site-related complications was similar for
ACD compared with mechanical compression. In the setting of PCI, the rate of complica-
tions appeared higher with VasoSeal. (J Am Coll Cardiol 2004;44:1200–9) © 2004 by the
American College of Cardiology FoundationM
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irteriotomy closure devices (ACD) have emerged as an
lternative to traditional mechanical compression after per-
utaneous coronary intervention (PCI) (1–2). These devices
ave the potential to reduce the time to hemostasis, facili-
ate patient mobilization, decrease hospital length of stay,
nd improve patient satisfaction (3–13). However, the issue
f ACD safety with respect to vascular complications
emains controversial (14). To provide an overall assessment
f vascular complications, we performed a meta-analysis of
ublished studies that evaluated the use of various ACD
ersus mechanical compression in patients undergoing cor-
nary procedures with the transfemoral approach.
From the *Cardiovascular Research Foundation and the Lenox Hill Heart and
ascular Institute, New York, New York; and †London School of Hygiene and
ropical Medicine, London, United Kingdom. The research fellowship program of
he Cardiovascular Research Foundation is a recipient of an educational grant from St.
ude Medical Inc.
Manuscript received February 18, 2004; revised manuscript received June 1, 2004,
tccepted June 9, 2004.ETHODS
iterature search and study selection. The methodology
f this meta-analysis was performed following the rec-
mmendations of the Cochrane Collaboration and Meta-
nalyses of Observational Studies in Epidemiology
MOOSE) group (15,16). To identify eligible manu-
cripts, a database search (Cochrane Library, MED-
INE, CINAHL, EMBASE) for literature published
ince 1991 was performed in April 2003 using the
ollowing keywords: “closure device,” “hemostasis,” “fem-
ral,” “arterial,” “vascular access,” “suture,” “collagen,”
angiography,” “angioplasty,” and “heart catheterization.”
n addition, the reference lists of the identified articles
ere critically reviewed.
Literature search and assessment of relevance of each
ource were performed by two independent reviewers (E.N.,
.H.). Disagreements about whether a trial should be
ncluded were resolved by discussion and adjudicated by a
hird reviewer (G.D.). Studies considered for the meta-
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September 15, 2004:1200–9 Arteriotomy Closure Devices: A Meta-Analysisnalysis included randomized control trials, cohort, and
ase-control studies that met all of the following criteria:
) were published as full articles; 2) had well-described
rotocols of intervention, including a precise report on each
f the major vascular complications; and 3) compared
ccess-related complications using ACD versus mechanical
ompression (manual, by means of hand compression,
andbag, C-clamp, or Femostop) in patients undergoing
CI with transfemoral access.
Pooled average rate of complications plus patients’ main
emographics and procedural data were extracted from each
anuscript. The primary outcome measure was cumulative
ncidence of major vascular complications, including pseu-
oaneurysm requiring ultrasound-guided compression or
urgical repair; arteriovenous fistula; retroperitoneal hema-
oma causing hemodynamic compromise, surgery, blood
ransfusion, prolonged hospitalization and/or death; femo-
al artery thrombosis (vessel occlusion requiring surgery or
hrombolysis); surgical vascular repair; access-site infection
ecessitating treatment with antibiotics and/or surgical
rainage; and blood transfusion.
Studies assessing Angio-Seal (Angio-Seal Daig,
innetonka, Minnesota) (3,6,9,11,12,17–23), VasoSeal
VasoSeal Datascope Inc., Montvale, New Jersey) (4,5,19,24–
0), and Perclose (ProStar Plus or TecStar; Perclose, Redwood
ity, California) (7,8,10,12,13,18,19,21,23,29,31–35) were in-
luded in the meta-analysis. Data on various devices as well as
n diagnostic (Dx) catheterization and PCI were assessed
eparately and in combination. In addition, a separate meta-
nalysis for randomized trials only was performed. Studies
sing different ACD sheath sizes were also analyzed.
tatistical analysis. All statistical analyses were per-
ormed using the software “Comprehensive Meta-
nalysis” (Biostat Inc., Englewood, New Jersey). Study
ffects are presented using odds ratios (OR). An odds
atio 1 indicates a better outcome for ACD, whereas an
R 1 indicates a better outcome for mechanical com-
ression. The OR and 95% confidence intervals (CI) for
ombined studies were calculated using Mantel-Haenszel
xed-effects models unless evidence of between-study
eterogeneity existed, in which case Mantel-Haenszel
andom effects models were used (36). The random
ffects model allows some of the variation in ORs
etween studies to reflect true underlying differences and
eads to a wider CI (36). Heterogeneity across studies in
Abbreviations and Acronyms
ACD  arteriotomy closure devices
CI  confidence interval
Dx  diagnostic
OR  odds ratio
PCI  percutaneous coronary intervention
RCT  randomized controlled trialhe meta-analysis was assessed using the Q statistic (15). pESULTS
total of 81 potentially eligible studies were identified. Of
hese, 51 were excluded (Appendix) for one or more of the
ollowing reasons: the lack of a control arm (n  31), ACD
se in a setting other than percutaneous coronary procedure
n  3), the lack of precise report on each of the major
ascular complications (n  8), combined analysis of vas-
ular complications in ACD group that included 1 device
n  3), bias in patient selection (n  3), review article
n  3), use of historical control (n  2), and repeat data
eporting (n  2).
The remaining 30 studies meeting the inclusion criteria
nd the important demographic and procedural determi-
ants of patient outcome are summarized in Tables 1 and 2.
he number of enrolled patients in the studies ranged from
0 to 10,001 (8,34), with 57% of studies having 100
atients in each arm. In all studies, most patients were men
range 56% to 94%) (5,8). The proportion of patients with
iabetes ranged from 8% to 43% (4,8). The majority of
tudies (73%) used a 8-F device sheath. There were no
ignificant baseline differences among ACD patients and
ontrol groups in each of the included studies.
The selected studies included a total of 37,066 patients
12,596 and 24,470 patients in the device and control
roups, respectively). Among the included publications,
here were 18 randomized studies (2,339 and 2,197 pa-
ients) (3–11,13,24 –28,31–33) and 12 nonrandomized
tudies (10,257 and 22,273 patients) (12,17–23,29,
0,34,35). In 12 studies, the ACD compared with mechan-
cal compression was Angio-Seal (3,6,9,11,12,17–23); in 9
tudies, VasoSeal (5,6,25–30); and in 15 studies, Perclose
7,8,10,12,13,18,19,21,23,31–35). Six studies compared
ore than one device versus conventional compression
echniques (12,18,19,21,23,29). Separate data on Dx and
CI procedures were provided in 6 (6,7,12,25,30,34) and 19
4,6–13,17,18,20–23,25–29,32–35) studies, respectively,
hereas 6 other studies presented mixed data on Dx and
CI procedures without clearly distinguishing between Dx
nd PCI settings (3,5,19,22,24,31).
ngio-Seal versus mechanical compression. Among 12
tudies that evaluated Angio-Seal versus mechanical com-
ression, 2 were conducted in the Dx setting, 8 in the
etting of PCI, and 4 presented results in a mixed setting
both Dx and PCI) (Fig. 1). Individual study sample sizes
aried from 150 to 6,262 patients (11,20). Two studies had
mall sample sizes (100 patients in each arm) (11,23).
tudies analyzing the use of Angio-Seal versus mechanical
ompression in either the Dx or PCI setting were statisti-
ally homogeneous (Fig. 1). However, significant heteroge-
eity in complication rates was present in studies that
nalyzed mixed Dx and PCI procedures, as well as all
tudies. Meta-analysis did not reveal a benefit for either
echnique in the setting of Dx (OR 0.71, 95% CI 0.22 to
.24), PCI (OR 0.86, 95% CI 0.65 to 1.12), or mixed
rocedures (OR 2.04, 95% CI 0.64 to 6.45), as well as in the
Table 1. Study and Patient Characteristics
Study (Ref.) Year
Procedure
Type
Patients Age, Mean  SD (yrs) Male (%) Diabetics (%)
Clinical
Follow-UpACD Control ACD Control ACD Control ACD Control
Angio-Seal
Kussmaul et al. (3)* 1995 DxPCI 218 217 61  11 62  NA 72.9 71.9 16.1 18.0 8 weeks
Ward et al. (6)* 1998 Dx, PCI† 202 102 61.7  12 64.7  10 69.3 70.6 24.3 25.5 14–30 days
Amin et al. (11)* 2000 PCI 75 75 58  NA 59.5  NA 77.3 78.7 21.3 20.0 In-hospital
Chevalier et al. (9)* 2003 PCI 306 306 70: 32% 70: 35% NA NA 17.0 19.0 7 days
Cremonesi et al. (17) 1998 PCI 411 387 59  15 55  18 77.5 76.9 20.7 25.1 In-hospital
Eidt et al. (22) 1999 DxPCI 425 1,662 51.7  NA NA 60.0 NA NA NA In-hospital
Cura et al. (18) 2000 PCI 411 2,099 63.1  11 63.5  11 76.9 69.0 25.1 30.5 In-hospital
Carey et al. (19) 2001 DxPCI 742 1,019 62  NA 63  NA 60.0 61.0 NA NA In-hospital
Dangas et al. (20) 2001 PCI 373 5,889 64 11 64  12 68.1 68.0 26.0 29.0 In-hospital
Duffin et al. (12) 2001 Dx, PCI† 537 469 63  13 63  13 70 65 17.0 19.0 30 days
Applegate et al. (21) 2002 PCI 524 1,824 62 12 64  12 55.9 63.0 25.0 20.0 In-hospital
Assali et al. (23) 2003 PCI 39 123 60  13.7 62.7  11.8 64.1 65.9 30.8 35.0 In-hospital
All Angio-Seal studies 4,263 14,172
VasoSeal
Schrader et al. (24)* 1992 DxPCI 50 50 58.5  10.2 58.5  9.2 86.0 90.0 NA NA 6 weeks
Sanborn et al. (25)* 1993 Dx, PCI† 246 209 60.6  NA 62.0  NA 73.6 67.5 17.9 16.7 30 days
Camenzind et al. (26)* 1994 PCI 62 62 59  12 60  11 80.6 85.5 NA NA In-hospital
Slaughter et al. (4)* 1995 PCI 51 50 57.0  10.5 57.7  9.3 82 74 8 14 28–35 days
Von Hoch et al. (27)* 1995 PCI 154 155 63  NA 60  NA 81.2 76.1 NA NA 3–7 days
Gwechenberger et al. (5)* 1997 DxPCI 33 29 59.8  8.1 56.9  10.8 93.9 82.8 NA NA 7 days
Silber et al. (28)* 1999 PCI 74 76 59.8  9.0 58  9.2 78.0 76.0 25.0 19.0 In-hospital
Chamberlin et al. (29) 1999 PCI 52 77 61.8  NA 63.7  NA 67.3 72.7 NA NA In-hospital
Schickel et al. (30) 1999 Dx 81 95 58.1  NA 52.8  NA 63.0 52.6 NA NA 3 days
Carey et al. (19) 2001 DxPCI 937 1,019 61  NA 63  NA 60.0 61.0 NA NA In-hospital
All VasoSeal studies 1,740 1,822
Perclose
Gerckens et al. (7)* 1999 Dx, PCI† 298 292 60  9 62  8 69.1 70.9 11.0 13.0 In-hospital
Baim et al. (31)* 2000 DxPCI 251 264 61.5  11.7 62.9  12.3 76.1 67.0 21.9 22.0 30 days
Carere et al. (32)* 2000 PCI 50 50 62  11 59  12 78.0 78.0 NA NA 3 days
Noguchi et al. (8)* 2000 PCI 30 30 63  10 61  12 90.0 83.3 43.3 40.0 In-hospital
Wetter et al. (33)* 2000 PCI 50 50 58.8  10.5 59.9  9.7 NA NA NA NA In-hospital
Rickli et al. (13)* 2002 PCI 96 97 62  11 59  10 74.0 83.5 NA NA In-hospital
Nasu et al. (10)* 2003 PCI 93 83 65  10 64  9 69.9 81.9 NA NA In-hospital
Cura et al. (18) 2000 PCI 408 2,099 63.6  11 63.5  11 72.1 69.0 24.5 30.5 In-hospital
Chamberlin et al. (29) 1999 PCI 56 77 62.9  NA 63.7  NA 71.4 72.7 NA NA In-hospital
Carey et al. (19) 2001 DxPCI 1,001 1,019 62  NA 63  NA 57.0 61.0 NA NA In-hospital
Duffin et al. (12) 2001 Dx, PCI† 492 469 62  12 63  13 70.0 71.0 17.1 19.0 30 days
Applegate et al. (21) 2002 PCI 2,177 1,824 62  12 64  12 71.0 63.0 25.0 20.0 In-hospital
Kahn et al. (34) 2002 Dx, PCI† 1,420 8,581 66.2  8 66.4  8 66.7 66.6 17.2 16.3 In-hospital
Kornowski et al. (35) 2002 PCI 48 48 64  13 63  13 70.8 64.6 20.8 22.9 In-hospital
Assali et al. (23) 2003 PCI 123 123 59.6  11.1 62.7  11.8 69.1 65.9 30.9 35.0 In-hospital
All Perclose studies 6,593 15,106
*Randomized studies. †Both separate and combined analysis is provided for diagnostic procedures and percutaneous coronary interventions.
ACD  arteriotomy closure device; Dx  diagnostic; NA  not available; PCI  percutaneous coronary interventions.
1202
Nikolsky
etal.
JACC
Vol.44,No.6,2004
Arteriotom
y
Closure
Devices:A
M
eta-Analysis
Septem
ber15,2004:1200–9
TA
V
P
A
S
1203JACC Vol. 44, No. 6, 2004 Nikolsky et al.
September 15, 2004:1200–9 Arteriotomy Closure Devices: A Meta-Analysisable 2. Device and Procedural Characteristics
Study (Ref.)
Device
Failure
(%)
Sheath Size
(F) in
ACD
Sheath Size
(F) in
Control
Dx Procedures
(%) Mean ACT  SD (s)
GP IIb/IIIa Use
(%)
ACD Control ACD Control ACD Control
ngio-Seal studies
Kussmaul et al. (3) 4.0 8 8F: 59.6% 74.8 70.0 176  69 156  53 0 0
8F: 40.4%
Cremonesi et al. (17) 4.1 8 8F: 45.6% 0 0 355  43 178  26 3.2 0
8F: 54.4%
Ward et al. (6) 4.0 8 8F: 97% 100.0 100.0 158.5  58 144.0  42 NA NA
8F: 3%
Eidt et al. (22) 8.0 8 NA NA NA NA NA NA NA
Amin et al. (11) 4.0 8 8F: 100% 0 0 NA NA 0 0
Cura et al. (18) 1.5 Mean Mean 0 0 264  NA 280  NA 56.0 58.0
7.8F  0.5 7.8F  0.5
Carey et al. (19) NA NA NA 29.0 30.0 NA NA 42.0 1.0
Dangas et al. (20) NA 8 NA 0 0 277  59 268  54 6.2 5.5
Duffin et al. (12) 4.5 8 8F: 70% 72.1 42.0 290  94 292  126 13.6 29.0
8F: 30%
Applegate et al. (21) 2.9 8F: 92% 8F: 5% 0 0 277  NA 268  NA 100.0 100.0
8F: 95%
Assali et al. (23) 15.4 8 8F: 91.1% 0 0 261  50 254  51 100.0 100.0
8F: 8.9%
Chevalier et al. (9) 3.2 8 8F: 92% 0 0 247  43 130  24 2.0 1.0
8F: 8.0%
asoSeal studies
Schrader et al. (24) 0 11.5 8F: 60% 60 60 NA NA 0 0
8F: 40%
Sanborn et al. (25) NA 11.5 8F: 29.2% 36.6 35.9 NA NA 0 0
8F: 70.8%
Camenzind et al. (26) 6.0 11.5 8F: 82% 0 0 NA NA 0 0
8F: 8%
Slaughter et al. (4) 20.0 8 8F: 100% 0 0 381  152 151  71 0 0
Von Hoch et al. (27) 0.0 11.5 8F: 100% 0 0 NA NA 0 0
Gwechenberger et al. (5) 0.0 11.5 NA 45.5 44.8 NA NA NA NA
Chamberlin et al. (29) 21.2 NA NA 0 0 172.7  NA 157.2  NA 100.0 100.0
Schickel et al. (30) NA NA NA 100.0 100.0 NA NA 0 0
Silber et al. (28) NA 11.5 NA 0 0 PTT reported PTT reported NA NA
Carey et al. (19) NA NA NA 15.0 30.0 NA NA 29.0 1.0
erclose studies
Chamberlin et al. (29) 14.3 NA NA 0 0 241  NA 157.2  NA 100.0 100.0
Gerckens et al. (7) 5.7 6F: 68.2% 5.5F to 8F 68.1 67.8 NA NA NA NA
8F: 31.8%
Baim et al. (31) 8.8 8F and 10F 8F: 42% 55.8 54.5 NA NA 8.0 12.9
8F: 58.0%
Carere et al. (32) 10.0 8 8F: 100% 0 0 350  92 157  64 0 0
Cura et al. (18) 1.5 Mean Mean 0 0 264  NA 280  NA 65.0 58.0
7.8F  0.5 7.8F  0.5
Noguchi et al. (8) 3.4 8 8F: 100% 0 0 288  49 151  27 NA NA
Wetter et al. (33) 8.0 6F: 33% 6F: 48% 0 0 290  83.6 277.4  67.2 0 0
7F: 67% 7F: 52%
Carey et al. (19) NA NA NA 29.0 30.0 NA NA 60.0 1.0
Duffin et al. (12) 8.9 6F or 8F 8F: 43% 0 0 316  103 292  126 35.8 50.0
8F: 57%
Applegate et al. (21) 2.9 8F-97% 8F: 5% 0 0 277  NA 268  NA 100.0 100.0
8F: 95%
Kahn et al. (34) 6.8 8 8F: 93.2% 0 0 205  26 202  24 100.0 100.0
8F: 6.8%
Kornowski et al. (35) 6.2 6 6F: 100% 0 0 247  68 262  87 58.3 43.8
Rickli et al. (13) NA 6F: 39 pts 6F: 55.7% 0 0 286  92 275  62 0 0
7P: 57 pts 7F: 44.3%
Assali et al. (23) 8.1 NA 8F: 91.1% 0 0 250  61 261  50 100.0 100.0
8F: 8.9%
Nasu et al. (10) NA 8F or 10F 7F to 8F: 95% 0 0 NA NA 0 0
9F to 10F: 5%
CD  arteriotomy closure device; Dx  diagnostic; GP  glycoprotein; NA  not available; PCI  percutaneous coronary interventions; PTT  partial thromboplastin time;
D  standard deviation.
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Arteriotomy Closure Devices: A Meta-Analysis September 15, 2004:1200–9verall assessment (OR 1.14, 95% CI 0.72 to 1.81). Meta-
nalysis of randomized trials only showed a trend toward
ess complications using Angio-Seal in a PCI setting (OR
.46, 95% CI 0.20 to 1.04; p  0.062). The results of
andomized studies in any setting were similar to the results
f all studies included in this analysis.
asoSeal versus mechanical compression. Among 10
tudies that evaluated VasoSeal versus mechanical compres-
ion, 2 were conducted in the Dx setting, 6 in the setting of
CI, and 4 in the mixed setting (Fig. 2). Individual study
ample sizes varied from 62 to 1,956 patients (5,19). The
ajority of studies (8 of 10) had small sample sizes. There was
o statistical evidence of heterogeneity across the studies (Fig.
). In the setting of Dx procedures, there was no significant
isk in complication rates in the ACD group compared with
echanical compression (OR 1.85, 95% CI 0.15 to 22.39);
owever, 2 identified studies included too small a number of
atients to draw conclusions. There was no significant differ-
nce in the incidence of vascular complications when studies on
ixed Dx and PCI procedures were analyzed together (OR
.86, 95% CI 0.85 to 4.06). However, meta-analysis favored
onventional technique in the setting of PCI (OR 2.52, 95%
igure 1. Odds ratio (OR) and 95% confidence interval (CI) of vascular
ompression (control) in diagnostic (Dx), percutaneous coronary interventio
Fixed effects model; †random effects model.I 1.36 to 4.65) and in any setting (OR 2.27, 95% CI 1.35 to.80). The results of meta-analysis of randomized trials only in
he setting of PCI and in any setting were close to the results
f meta-analysis of all studies.
erclose versus mechanical compression. Fifteen studies
valuated Perclose versus mechanical compression: 3 in the
x setting, 13 in the setting of PCI, and 5 in the mixed
etting (Fig. 3). Individual study sample sizes varied from 60
o 10,001 patients (8,34). Eight studies were small, repre-
enting 53.3% of all Perclose studies. Statistical evidence of
eterogeneity for the complication rate was present in
tudies assessing Dx and mixed procedures as well as in all
tudies, but not in studies related to PCI (Fig. 3). No
ifference in the risk of complications was found in studies
ssessing ACD versus mechanical compression in either
etting (OR 1.51, 95% CI 0.24 to 9.47 for Dx; OR 1.21,
5% CI 0.94 to 1.54 for PCI; and OR 1.37, 95% CI 0.88 to
.14 for any setting).
Again, the results of meta-analysis of randomized trials
ssessed only in the setting of PCI, mixed setting, or any
etting were similar to the results of meta-analysis of all studies.
ny device versus mechanical compression. When all
tudied devices were analyzed versus mechanical com-
ression, statistical evidence of heterogeneity was present
s-related complication rate in patients with Angio-Seal and mechanical
I), mixed (DxPCI), or any setting. RCT randomized controlled trials.acces
n (PC
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September 15, 2004:1200–9 Arteriotomy Closure Devices: A Meta-Analysiscross studies related to 1) Dx procedures, 2) mixed Dx
nd PCI procedures, and 3) any procedure. There was no
ignificant heterogeneity across randomized trials only in
ither setting. There was no significant difference in the
isk of complications using either technique in the
andomized trials. The same was also found in the
eta-analysis of all studies in the Dx and PCI settings.
eta-analysis of all included studies in mixed Dx and
CI setting and all settings together favored conventional
echnique over ACD (Fig. 4).
ercutaneous coronary interventions using glycoprotein
Ib/IIIa inhibitors. Major vascular complication rates us-
ng Angio-Seal or Perclose versus mechanical compression
n patients treated with glycoprotein IIb/IIIa inhibitors were
ompared in three and four studies, respectively
8,21,23,29,34). There was no evidence of significant het-
rogeneity across these studies (p  0.30 and 0.76, respec-
ively). The use of either Angio-Seal or Perclose was
ssociated with similar complication rates to mechanical
ompression (OR 1.17, 95% CI 0.87 to 1.58; and OR 1.05,
igure 2. Odds ratio (OR) and 95% confidence interval (CI) of vascula
ompression (control) in diagnostic (Dx), percutaneous coronary interven
ontrolled trials.5% CI 0.77 to 1.44, respectively). dercutaneous coronary interventions using different de-
ice sheath size. Of nine studies applying Perclose in the
CI setting, four studies used closure device with sheath
ize 6- or 7-F (7,13,33,35) whereas the device sheath size
as 8 French in the other five studies (8,10,21,32,34).
here was no evidence of heterogeneity between studies
ncluded in either group (p  0.95 and 0.91, respectively).
he use of Perclose was associated with the same risk of
omplications as traditional compression regardless of de-
ice sheath size (OR 0.76, 95% CI 0.27 to 2.19 for the
maller sheath; OR 1.12, 95% CI 0.81 to 1.54 for the larger
heath).
ISCUSSION
he present meta-analysis found no significant risk with
espect to vascular complications between ACD and me-
hanical compression in the setting of diagnostic proce-
ures; the same was applicable for the PCI setting, with the
xception of the VasoSeal device, which appeared to have a
ess-related complication rate in patients with VasoSeal and mechanical
(PCI), mixed, or any setting. *Fixed effects model. RCT  randomizedr acc
tionisadvantage compared to mechanical compression.
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ng important issues regarding our approach to this meta-
nalysis should be addressed. Primarily, our meta-analysis
ncluded both randomized and observational trials because
he current literature lacks large-scale randomized control
rials with sample size sufficient to reveal superiority or
oninferiority of ACD compared with mechanical com-
ression. In fact, the proportion of patients from random-
zed trials in the current analysis was rather low: only 8% in
ngio-Seal and Perclose studies, 36% in the VasoSeal
tudies, and 10% in all studies.
The application of meta-analysis to observational studies
as been advocated when large randomized trials are not
vailable (16). However, there are potentially more bias
ources in these studies relative to randomized trials. This
ay make an estimation of a single outcome potentially
isleading. Inclusion of small (even randomized) studies
nto a meta-analysis might limit power to detect difference
n major complications because of relatively low incidence of
igure 3. Odds ratio (OR) and 95% confidence interval (CI) of vascul
ompression (control) in diagnostic (Dx), percutaneous coronary intervent
CT  randomized controlled trials.his outcome measure. This was especially true in the (nalysis of VasoSeal: 8 of 10 studies on this device had
100 patients in each arm. In addition, the issue of
ublication bias may threaten the validity of any meta-
nalysis, especially for observational studies. Failure to
nclude unpublished trials introduces bias toward overesti-
ating the effectiveness of an intervention (in this case,
CD).
Given the differences of patients that may be included in
andomized controlled trials (RCT) and other studies, we
lso performed a meta-analysis of RCT only on this subject.
he results in the setting of PCI were similar to the overall
esults. However, given the paucity of trials in the setting of
iagnostic procedures, it was not possible to perform a
eta-analysis separately for RCT in this setting.
he issue of heterogeneity. Several baseline characteristics
f included patients and study design details differed among
he analyzed trials. These discrepancies may have contrib-
ted to the heterogeneous results. The sources of heteroge-
eity in ACD studies are various and are related to patient
ess-related complication rate in patients with Perclose and mechanical
CI), mixed, or any setting. *Fixed effects model; †random effects model.ar acc
ion (Page, gender, body mass index, the presence of diabetes, and
p
a
(
p
m
a
c
t
r
f
u
f
o
a
c
r
g
e
V
b
l
i
m
m
G
i
s
m
d
s
t
o
b
S
d
f
t
A
s
d
w
R
b
m
s
t
p
c
c
t
a
s
d
t
b
(
d
m
h
s
i
(
o
s
p
F
(
s
1207JACC Vol. 44, No. 6, 2004 Nikolsky et al.
September 15, 2004:1200–9 Arteriotomy Closure Devices: A Meta-Analysiseripheral arterial disease), operator (individual experience
nd learning curves for each device), and/or procedure
femoral artery puncture site, sheath size, first versus repeat
rocedure, level of anticoagulation before the vascular he-
ostasis, and the mode of adjunctive pharmacotherapy).
Finally, the different study methodologies may be an
dditional reason for the between-study heterogeneity. Spe-
ifically, the indications for and the timing of blood product
ransfusions were not specified in the included studies, but
ather left to local standards of care. Diversity of methods
or the diagnosis of complications (e.g., clinical only vs.
ltrasound-guided approach) and different durations of
ollow-up are the obvious reasons for the difference in the
btained results. This is especially true with regard to
ssessing rates of hematomas. In the included studies,
riteria for the definition of groin hematoma had a very wide
ange (Table 3). Taking this consideration into account,
roin hematoma was not considered a primary end point.
There was no statistically significant heterogeneity in
ither diagnostic or PCI setting in the Angio-Seal and
asoSeal studies. As for Perclose, the studies were found to
e heterogeneous only in the diagnostic setting. The fol-
owing sources of heterogeneity in the latter studies were
dentified: patients in the study of Kahn et al. (34), favoring
echanical compression versus Perclose, were older and
ore frequently diabetic than patients in the study of
erckens et al. (7), reporting similar rates of complications
n both groups. The study by Duffin et al. (12), the third
tudy in the diagnostic setting that also did not favor either
ode of hemostasis, had longer duration of follow-up (30
ays) than two previous studies (7,34) (in-hospital stay
olely).
Remarkably, studies assessing vascular complications in
he setting of mixed procedures (both diagnostic and PCI)
igure 4. Odds ratio (OR) and 95% confidence interval (CI) of vascular a
ACD) and mechanical compression (control) in diagnostic (Dx), percutane
quares  randomized studies.r in any setting (diagnostic, PCI, and both) were shown to Ke significantly heterogeneous (except for VasoSeal trials).
uch heterogeneity is probably attributed to the principal
ifference in main procedural characteristics (primarily dif-
erent sheath size and anticoagulation regimen). Therefore,
o avoid obvious heterogeneity, the proper assessment of any
CD versus traditional compression should be performed
eparately for the diagnostic and PCI setting, and each
evice, not the entire device entity, should be compared
ith mechanical compression.
elationship to current literature. Our results should also
e interpreted within the context of the recently published
eta-analysis by Koreny et al. (14), assessing efficacy and
afety of ACD in patients undergoing cardiac catheteriza-
ion. Koreny et al. (14) incorporated data on about 4,000
atients from 30 randomized studies; ACD and mechanical
ompression were associated with similar risk of local
omplications. In the same publication, using intention-to-
reat data solely, the risk of hematoma and pseudoaneurysm
ppeared to be higher using ACD.
Despite general methodologic similarity between the
tudy by Koreny et al. and our study, several principal
ifferences exist. First is the different approach in defining
he access site-related complications. The definition given
y the individual study author was used by Koreny et al.
14); the ambiguity of including hematoma was discussed in
etail earlier, and inclusion of this complication in the
eta-analysis is subject to the tremendous variability of
ematoma definitions (and assessment) among the various
tudies. Second, no separate analysis on diagnostic and
nterventional procedures was presented by Koreny et al.
14); vascular complications are known to depend primarily
n the procedure type, and the anticoagulation and sheath
ize differ a great deal between diagnostic and interventional
rocedures (1,2). Third, 12 of 30 studies analyzed by
-related complication rate in patients with any arteriotomy closure device
ronary intervention (PCI), mixed, or any setting. Diamonds all studies;ccess
ous cooreny et al. (14) were reported in abstract form, which is
n
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o consensus regarding this issue, we chose to include only
ublished studies providing detailed information on meth-
dology, end point definitions, and outcomes.
ther criteria for ACD assessment. In our study, we
ocused principally on the comparison of complication rates
sing ACD versus mechanical compression for hemostasis
ecause this matter has been in debate (14). Other impor-
ant aspects in the assessment of ACD include efficacy of
he specific device, time to hemostasis, ambulation and
ischarge, patient viewpoint, and cost-effectiveness. The
nalyzed studies had a wide range of ACD failure (up to
0%); this is certainly an important consideration in the
able 3. Definition of Hematoma in Studies Included in the
eta-Analysis
Study (Ref.) Definition of Hematoma
min et al. (11) 5, 5 to 10, and 10 cm in diameter
pplegate et al. (21) 10 cm in diameter
ssali et al. (23) 5 cm in diameter
aim et al. (31) Hematoma was not included as an
end point
arere et al. (32) 5, 5 to 10, and 10 cm in diameter
arey et al. (19) No definition of hematoma; hematoma
was not included as an end point
amenzind et al. (26) 10, 10 to 20, and 20 cm in
diameter
hamberlin et al. (29) Hematoma requiring blood transfusion
or an extended hospital stay
hevalier et al. (9) 6 cm in diameter
remonesi et al. (17) 6 cm, requiring surgical repair
ura et al. (18) 5 cm in diameter
angas et al. (20) Blood accumulation 2  4 cm or
requiring transfusion or resulting in
prolonged hospitalization
uffin et al. (12) Any significant hematoma reported by
the cardiovascular nurse based on
standard guidelines
idt et al. (22) Hematoma sufficient to warrant surgical
consultation
erckens et al. (7) 4 cm in diameter
wechenberger et al. (5) 6  6 cm
ahn et al. (34) Large hematoma: accumulation of
subcutaneous blood 2 cm in
diameter, small hematoma: 2 cm
ornowski et al. (35) 10 cm in diameter
ussmaul et al. (3) Any palpable mass
asu et al. (10) 0.5 to 3 cm and 3 cm in diameter
oguchi et al. (8) Hematoma 5 or 5 cm in diameter
ickli et al. (13) Hematoma 1 ml on ultrasound
examination
anborn et al. (25) 2 to 6 cm and 6 cm in diameter
chickel et al. (30) 2 to 6 cm and  6 cm in diameter
chrader et al. (24) 6 cm in diameter
laughter et al. (4) 2 to 6 cm and 6 cm in diameter
ilber et al. (28) 7, 7 to 15, and 15 cm in diameter
on Hoch et al. (27) Hematoma was not included as a
complication
ard et al. (6) 6 cm or 6 cm in diameter
etter et al. (33) Hematoma 1 ml on ultrasound
examinationverall assessment of ACD, and it understandably improvesith newer generations of devices and with operator
xperience.
The majority of the included studies demonstrated a
educed time to hemostasis and ambulation in both the
iagnostic and PCI settings using ACD versus mechanical
ompression (3–10,12,13,23–25,28,31–33,35); the critical
ssue has been a potential tradeoff of safety with ACD use,
s we suggested in our previous study with the very early
CD generations (20) and another recent meta-analysis has
peculated (14). According to our present meta-analysis, no
uch concern appears justifiable for most ACD types.
Only a few studies have assessed patient viewpoint using
vascular closure device; this is because little dispute exists
n the fact that ACD application does improve patient
atisfaction and time to ambulation (8,10–13,30,32). In-
eed, the majority of studies have reported that patient
atisfaction was higher using ACD (Angio-Seal and Per-
lose) than mechanical compression (8,10–13,32); however,
wo studies showed no difference in the level of patient
atisfaction using ACD (Perclose and VasoSeal) compared
ith manual compression (12,30). Only two studies dem-
nstrated a reduction of in-hospital stay (8,10) and costs
8,13) using Perclose compared with mechanical compres-
ion.
tudy limitations. Because of the specifics of the proce-
ure to achieve hemostasis, blinding is not possible even in
andomized trials of ACD. Relatively small percentages of
omen were included in the trials. This meta-analysis still
overed publications mostly related to the early generations
f ACD. Rapidly advancing device technologies may
hange the position of ACD compared to the conventional
ompression technique. Additional studies are required to
xamine the safety of ACD and the impact of generational
dvances of these devices on outcomes.
onclusions. In the setting of Dx cardiac catheterization,
he risk of vascular complications related to arterial access
ite was similar with all three devices when compared with
echanical compression. In the setting of PCI, Angio-Seal
nd Perclose were similar to mechanical compression. The
ate of complications after PCI was higher with VasoSeal
ompared to mechanical compression. Despite inherent bias
nd differences in study designs, our meta-analysis may
rovide a helpful tool to understand the sources of variabil-
ty in results across studies and to improve the design of
uture studies on ACD.
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